UK Cancer Immunotherapy Market Size & Outlook, 2023-2030
UK cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
UK cancer immunotherapy market highlights
- The UK cancer immunotherapy market generated a revenue of USD 4,992.8 million in 2023 and is expected to reach USD 9,543.4 million by 2030.
- The UK market is expected to grow at a CAGR of 9.7% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 4,992.8 million |
| Market revenue in 2030 | USD 9,543.4 million |
| Growth rate | 9.7% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, UK accounted for 4.0% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 6,410.1 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 65.83% in 2023. Horizon Databook has segmented the UK cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Cancer incidence has increased by 12% since the 1990s in the UK. The prevalence of cancer is slightly higher in men (51%) than in women (49%). Furthermore, Wales and Scotland recorded higher cancer incidence than England and Ireland.
The cancer diagnosis scenario in the UK is fairly good as nearly 55% of cases are identified at early stages, whereas roughly 26% cases are diagnosed at advanced stages. The UK recorded the 11th highest cancer incidence among all European countries in 2018.
The Royal Marsden NHS Foundation Trust and the Macmillan Cancer Support are some of the notable organizations focused on funding cancer research in the UK. Some of the top trends in the country pertaining to cancer immunotherapy are genetically engineered viral therapies, combinatorial approaches in immunotherapy, and adjuvant treatment strategies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK cancer immunotherapy market size, by product, 2018-2030 (US$M)
UK Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
